Literature DB >> 15010875

Expression of Smac/DIABLO is a novel prognostic marker in lung cancer.

Atsushi Sekimura1, Akimitsu Konishi, Kotaro Mizuno, Yoshihiro Kobayashi, Hidefumi Sasaki, Motoki Yano, Ichiro Fukai, Yoshitaka Fujii.   

Abstract

Recently Smac/DIABLO (second mitochondria-derived activator of caspase) has been identified as a proapoptotic protein that inhibits IAPs (inhibitors of apoptosis proteins). Smac is expressed ubiquitously in many organs, including the lung. Here we evaluated the expression of Smac mRNA with real-time reverse-transcription PCR in 88 primary lung cancers and matched normal tissues. Smac mRNA expression in tumor tissues was significantly lower than that in normal tissues (p<0.0001). In squamous cell carcinomas, Smac mRNA expression was significantly lower than that in adenocarcinomas (p=0.0072). Smac mRNA expression in T2-T4 tumors was significantly lower than that in T1 tumors (p=0.0006). The expression of Smac in the tumors of smokers was lower than that in the tumors of non-smokers (p=0.0011). The prognosis of patients with a tumor exhibiting a low expression of Smac mRNA was worse than that in those with a tumor exhibiting high Smac mRNA expression (log-rank test, p=0.047). These results indicate that Smac expression may play a role in the carcinogenesis, progression, and prognosis of primary lung cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15010875

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  20 in total

1.  BV6, an IAP antagonist, activates apoptosis and enhances radiosensitization of non-small cell lung carcinoma in vitro.

Authors:  Wenyan Li; Bo Li; Nicholas J Giacalone; Artour Torossian; Yunguang Sun; Kathy Niu; Opal Lin-Tsai; Bo Lu
Journal:  J Thorac Oncol       Date:  2011-11       Impact factor: 15.609

Review 2.  Targeting IAP proteins for therapeutic intervention in cancer.

Authors:  Simone Fulda; Domagoj Vucic
Journal:  Nat Rev Drug Discov       Date:  2012-02-01       Impact factor: 84.694

3.  Prognostic value of Smac expression in rectal cancer patients treated with neoadjuvant therapy.

Authors:  Hongjiang Yan; Jinming Yu; Renben Wang; Shumei Jiang; Kunli Zhu; Dianbin Mu; Zhongfa Xu
Journal:  Med Oncol       Date:  2011-01-25       Impact factor: 3.064

4.  Debio 1143, an antagonist of multiple inhibitor-of-apoptosis proteins, activates apoptosis and enhances radiosensitization of non-small cell lung cancer cells in vitro.

Authors:  Ningbo Liu; Zhen Tao; Justin M Le Blanc; Nicholas G Zaorsky; Yunguang Sun; Grégoire Vuagniaux; Adam P Dicker; Bo Lu
Journal:  Am J Cancer Res       Date:  2014-11-19       Impact factor: 6.166

5.  Expression of apoptosome pathway-related transcripts in non-small cell lung cancer.

Authors:  Evzen Krepela; Jan Procházka; Pavel Fiala; Petr Zatloukal; Pavel Selinger
Journal:  J Cancer Res Clin Oncol       Date:  2005-10-18       Impact factor: 4.553

6.  Array-based gene expression, CGH and tissue data defines a 12q24 gain in neuroblastic tumors with prognostic implication.

Authors:  Maija Wolf; Miikka Korja; Ritva Karhu; Henrik Edgren; Sami Kilpinen; Kalle Ojala; Spyro Mousses; Anne Kallioniemi; Hannu Haapasalo
Journal:  BMC Cancer       Date:  2010-05-05       Impact factor: 4.430

7.  Predictive value of Smac, VEGF and Ki-67 in rectal cancer treated with neoadjuvant therapy.

Authors:  Hongjiang Yan; Renben Wang; Jinming Yu; Shumei Jiang; Kunli Zhu; Dianbin Mu; Zhongfa Xu
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

8.  Expression levels of the mitochondrial IAP antagonists Smac/DIABLO and Omi/HtrA2 in clear-cell renal cell carcinomas and their prognostic value.

Authors:  Carsten Kempkensteffen; Stefan Hinz; Frank Christoph; Hans Krause; Ahmed Magheli; Mark Schrader; Martin Schostak; Kurt Miller; Steffen Weikert
Journal:  J Cancer Res Clin Oncol       Date:  2007-10-09       Impact factor: 4.553

9.  Low circulating serum levels of second mitochondria-derived activator of caspase (Smac/DIABLO) in patients with bladder cancer.

Authors:  Yoichi Mizutani; Yoji Katsuoka; Benjamin Bonavida
Journal:  Int J Oncol       Date:  2012-01-03       Impact factor: 5.650

10.  Microarray-based cancer prediction using soft computing approach.

Authors:  Xiaosheng Wang; Osamu Gotoh
Journal:  Cancer Inform       Date:  2009-05-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.